Teva Pharmaceuticals USA, Inc., a US affiliate of Israel-based Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced on Thursday that new findings will be presented at the 2022 American Thoracic Society (ATS) 2022 Annual Meeting that apply clinical thresholds for short-acting beta agonist (SABA) use established by independent expert consensus to objective patient data from ProAir Digihaler (albuterol sulfate) Inhalation Powder.

These findings are the first to examine daily SABA usage captured by the ProAir Digihaler based on the clinical thresholds and will be presented in a late-breaker oral session at the 2022 ATS Annual Meeting, taking place on 13-18 May 2022, in San Francisco.

'Asthma is a common and serious chronic lung disease that affects the airways, which can make breathing difficult. SABA inhalers are used to get treatment to the lungs quickly during an exacerbation or asthma attack, but its overuse is associated with poorly controlled asthma and other adverse outcomes,' said Tanisha Hill, senior medical director, Respiratory at Teva. 'Our latest data at ATS will showcase how objective data from ProAir Digihaler, an FDA-approved reliever medication with a built-in sensor, could help capture reliable reliever usage and inhaler event data that physicians and their patients can use to help support informed treatment discussions and assessments.'

This presentation can be accessed by registering for the meeting at https://conference.thoracic.org/attendees/.